BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Quetiapine (Seroquel XR) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Quetiapine (Seroquel XR)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07152184-7470@assetmemo.bio
DTSTAMP:20261121T005956Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Quetiapine (Seroquel XR): Phase 2 readout est. (NCT07152184)
DESCRIPTION:Quetiapine (Seroquel XR)\, phase 2\, Schizophrenia.\nStudy: Stu
 dy Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Pat
 ients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approa
 ch\nEstimated primary completion: 1 February 2032. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/quetiapine-seroquel-xr#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07152184
URL:https://assetmemo.bio/drug/quetiapine-seroquel-xr#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
